Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

Novo Nordisk is working on a new obesity drug that could help patients shed more than any other weight-loss drug on the ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Semaglutide, and other GLP-1 drugs like it, have experienced shortages in the past two years as millions of Americans have turned to the medications for help with significant weight loss. While ...

See Also GLP-1s masterfully reduce the amount of inflammation in the body by stimulating weight loss, interacting with immune ...

Lars Fruergaard Jørgensen began his career at Novo Nordisk as an economist in the health care, economy, and planning ...

That move alone nearly doubled Pfizer’s revenues in fiscal year 2021 to around $81.3 billion. Since then, the company has ...

These pose a health risk to the public. Sahpra cautions the public to not purchase and/or consume such products as their ...

The South African Health Products Regulatory Authority (SAHPRA) has expressed concern at the increasing presence of counterfeit Glucagon-like ...

Despite these slips, both Novo Nordisk and Lilly retained their dominant market positions, bolstered by the still high demand ...